PCMA: Anti-biosimilars measures put profits over patients

02/28/2013 | Bloomberg BNA (subscription required)

State legislation that would restrict dispensing biosimilars would raise drug costs for patients, employers and public health programs, PCMA says. "[C]ampaigning to restrict the use of biosimilars enriches brand manufacturers at the expense of the employers, public health programs, and patients who need access to lower cost medicines," PCMA President and CEO Mark Merritt said.

View Full Article in:

Bloomberg BNA (subscription required)